On May 15, 2020 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, reported the results from its Annual General Meeting ("AGM") held today, May 15, 2020 (Press release, AEterna Zentaris, MAY 15, 2020, View Source [SID1234558220]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The individuals noted below were elected as Directors of the Company. The report on proxies provided by the Company’s transfer agent indicated the following:

The Company would like to welcome Peter Edwards to the Board of Directors.

The Company would also like to extend its sincere thanks and best wishes to Gérard Limoges, Dr. Brent Norton, and Robin Smith Hoke who have been valued members of Aeterna’s Board of Directors.

The Company also reported the re-appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor.

For full voting details please see the voting results of Aeterna Zentaris Inc. as filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov.